Hepatitis C virus-human immunodeficiency virus coinfection

Liver International

Volumn 32, Issue SUPPL. 1, 2012, Pages 129-134

  Sulkowski, Mark S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Boceprevir; HCV; HIV; Peginterferon; Ribavirin; Telaprevir

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ANTIRETROVIRUS AGENT; ATAZANAVIR; BOCEPREVIR; DARUNAVIR; EFAVIRENZ; EMTRICITABINE; FOSAMPRENAVIR; LAMIVUDINE; LOPINAVIR; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RALTEGRAVIR; RIBAVIRIN; RITONAVIR; TELAPREVIR; TENOFOVIR; VIRUS RNA;

ANTIVIRAL THERAPY; AREA UNDER THE CURVE; BODY WEIGHT; DISEASE COURSE; DRUG ANTAGONISM; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; GENOTYPE; HEPATITIS C; HISTORY OF MEDICINE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TOXICITY; META ANALYSIS (TOPIC); MIXED INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEXUAL TRANSMISSION; UNSPECIFIED SIDE EFFECT; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; COINFECTION; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; MALE; OLIGOPEPTIDES; PATIENT SELECTION; POLYETHYLENE GLYCOLS; PROLINE; RECOMBINANT PROTEINS; RIBAVIRIN; SERINE PROTEINASE INHIBITORS; TREATMENT FAILURE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84855232974     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02719.x     Document Type: Review

References (39)

1. Smith C. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D study. AIDS 2010; 24: 1537-48.
2. Monto A, Schooley RT, Lai JC, et al. Lessons from HIV therapy applied to viral hepatitis therapy: summary of a workshop. Am J Gastroenterol 2010; 105: 989-1004.
3. Pineda JA, Gonzalez J, Ortega E, et al. Prevalence and factors associated with significant liver fibrosis assessed by transient elastometry in HIV/hepatitis C virus-coinfected patients. J Viral Hepat 2010; 17: 714-9.
4. Urbanus AT, van de Laar TJ, Stolte IG, et al. Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic. AIDS 2009; 23: F1-7.
5. Subramanian A, Sulkowski M, Barin B, et al. MELD score is an important predictor of pretransplantation mortality in HIV-infected liver transplant candidates. Gastroenterology 2010; 138: 159-64.
6. Salmon-Ceron D, Rosenthal E, Lewden C, et al. Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: the French national Mortalite 2005 study. J Hepatol 2009; 50: 736-45.
7. Duclos-Vallee JC, Feray C, Sebagh M, et al. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2008; 47: 407-17.
8. Mehta SH, Genberg BL, Astemborski J, et al. Limited uptake of hepatitis C treatment among injection drug users. J Community Health 2008; 33: 126-33.
9. Mehta SH, Lucas GM, Mirel LB, et al. Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS 2006; 20: 2361-9.
10. Thomas DL. The challenge of hepatitis C in the HIV-infected person. Annu Rev Med 2008; 59: 473-85.
11. Staples CT, Jr., Rimland D, Dudas D. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival. Clin Infect Dis 1999; 29: 150-4.
12. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002; 34: 831-7.
13. Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Hepatitis C and progression of HIV disease. JAMA 2002; 288: 199-206.
14. Paintsil E, He H, Peters C, Lindenbach BD, Heimer R. Survival of hepatitis C virus in syringes: implication for transmission among injection drug users. J Infect Dis 2010; 202: 984-90.
15. Strickland GT. Liver disease in Egypt: hepatitis C superseded schistosomiasis as a result of iatrogenic and biological factors. Hepatology 2006; 43: 915-22.
16. van de Laar T, Pybus O, Bruisten S, et al. Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. Gastroenterology 2009; 136: 1609-17.
17. Danta M, Brown D, Bhagani S, et al. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS 2007; 21: 983-91.
18. Crepaz N, Hart TA, Marks G. Highly active antiretroviral therapy and sexual risk behavior: a meta-analytic review. JAMA 2004; 292: 224-36.
19. Eyster ME, Diamondstone LS, Lien JM, et al. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr 1993; 6: 602-10.
20. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis c virus infection: a meta-analysis. Clin Infect Dis 2001; 33: 562-9.
21. Qurishi N, Kreuzberg C, Lüchters G, Effenberger W, Kupfer B, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C coinfection. Lancet 2004; 362: 1708-13.
22. Brau N, Salvatore M, Rios-Bedoya CF, et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006; 44: 47-55.
23. Sherman KE, Andersen JW, Butt AA, et al. Sustained long-term antiviral maintenance therapy in HCV/HIV-Coinfected patients (SLAM-C). J Acquir Immune Defic Syndr 2010; 15: 597-605.
24. Sterling RK, Wegelin JA, Smith PG, et al. Similar progression of fibrosis between HIV/HCV-infected and HCV-infected patients: analysis of paired liver biopsy samples. Clin Gastroenterol Hepatol 2010; 8: 1070-6.
25. Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS 2008; 22: 1979-91.
26. PEGASYS (peginterferon alfa-2a) Prescribing Information. Revised March 2010. Nutley, NJ: Hoffman-La Roche Inc., 2010.
27. PEGINTRON (peginterferon alfa-2b) Prescribing Information. Revised January 2010. Kenilworth, NJ: Schering Corporation, 2010.
28. Hadziyannis SJ, Sette H, Jr., Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.
29. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438-50.
30. Rodriguez-Torres M, Lea SJB. Standard versus high dose ribavirin in combination with peginterferon alfa-2a in genotype 1 HCV patients coinfected with HIV: final results of the PARADIGM study [Abstract]. Program and abstracts of the 60th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA, USA, 2009 Nov 3; Abstract 1561.
31. Shire NJ, Welge JA, Sherman KE. Response rates to pegylated interferon and ribavirin in HCV/HIV coinfection: a research synthesis. J Viral Hepat 2007; 14: 239-48.
32. Chung RT, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351: 451-9.
33. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292: 2839-48.
34. Laguno M, Murillas J, Blanco JL, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004; 18: F27-36.
35. Nunez M, Miralles C, Berdun MA, et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses 2007; 23: 972-82.
36. Laguno M, Cifuentes C, Murillas J, et al. Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology 2009; 49: 22-31.
37. Sulkowski MS, Kea DDDKS. Interim Analysis of a Phase 2a Double-blind Study of TVR in Combination with pegIFN-a2a and RBV in HIV/HCV Co-infected Patients [Abstract]. 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 2011 Mar 2; Abstract 146LB.
38. Sulkowski MS. Boceprevir plus peginterferon/ribavirin for the treatment of HCV/HIV co-infected patients [Abstract]. Infectious Diseases Society of America Meeting. Boston, MA, USA, 2011, Oct 22; Abstract LB-37.
39. Seden K, Back D, Khoo S. New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals. J Antimicrob Chemother 2010; 65: 1079-85.